Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

State Drug Transparency Laws: Considerations for Pharmaceutical Manufacturers (AHLA’s 2021 Health Law Watch)

Related Content

A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond

Additional Disclosure Required: CMS Implements Substantial Changes to Reporting Skilled Nursing Facility Ownership Information

A Look Ahead in Life Sciences: What We Are Tracking in Q3 2023 and Beyond

CMS Issues Guidance and Solicits Comment on the 2026 Inflation Reduction Act Part D Negotiation Process

In the Metaverse, Existing Healthcare Rules Apply

Implications of Abortion Laws for Fertility Services

Congress Expands Pathway for Drug & Device Manufacturers’ Pre-Approval Communication of Health Care Economic Information to Payors, Formularies, & Similar Entities

DOJ False Claims Act Recoveries Exceed $5.6 Billion in 2021

New Drug Patent Proposal Sparks Worry Over Gov't Overstep (Law360)

Goodwin Advises Braidwell on $200 Million Term Loan and Warrant Investment in Nevro Corp.

Goodwin Represents the Initial Purchasers and Dealers on Amphastar Pharmaceuticals, Inc.’s $345 million 2.00% Convertible Senior Notes Offering

Rapport Therapeutics Completes $150 Million Series B

Nanobiotix Enters Into Licensing, Co-Development, And Commercialization Agreement With Janssen

Versanis Bio To Be Acquired By Eli Lilly In A Transaction Valued Up To $1.925 Billion

EGP Leads $30 Million Series A Funding for Uwill

'Fog Of War' No Alibi? Outbreak Case's Ruling Bolsters Gov't (Law360)

Healthcare

Life Sciences

Healthcare Regulatory